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ABSTRACT
Trans-arterial radioembolization (TARE) is a recognized, although not explicitly 
recommended, experimental therapy for unresectable hepatocellular carcinoma 
(HCC). 
A systematic literature review was performed to identify published studies on 
the use of TARE in intermediate and advanced stages HCC exploring the efficacy and 
safety of this innovative treatment.
Twenty-one studies reporting data on overall survival (OS) and time to 
progression (TTP), were included in a meta-analysis. The pooled post-TARE OS was 
63% (95% CI: 56-70%) and 27% (95% CI: 21-33%) at 1- and 3-years respectively 
in intermediate stage HCC, whereas OS was 37% (95% CI: 26-50%) and 13% 
(95% CI: 9-18%) at the same time intervals in patients with sufficient liver function 
(Child-Pugh A-B7) but with an advanced HCC because of the presence of portal vein 
thrombosis. When an intermediate and advanced case-mix was considered, OS was 
58% (95% CI: 48-67%) and 17% (95% CI: 12-23%) at 1- and 3-years respectively. 
As for TTP, only four studies reported data: the observed progression probability was 
56% (95% CI: 41-70%) and 73% (95% CI: 56-87%) at 1 and 2 years respectively. 
The safety analysis, focused on the risk of liver decompensation after TARE, revealed 
a great variability, from 0-1% to more than 36% events, influenced by the number 
of procedures, patient Child-Pugh stage and treatment duration.
Evidence supporting the use of radioembolization in HCC is mainly based on 
retrospective and prospective cohort studies. Based on this evidence, until the results 
of the ongoing randomized trials become available, radioembolization appears to be 
a viable treatment option for intermediate-advanced stage HCC.
INTRODUCTION
Hepatocellular carcinoma represents the third most 
common cause of cancer death, causing nearly 746,000 
deaths per year in the world [1, 2]. In almost all cases, one 
risk factor can be identified alone or in combination with 
others, with cirrhosis being the most frequent of them [3]. 
Prognosis of patients with HCC is poor, with a ratio of 
mortality to incidence of 0.95 [2]. Indeed HCC represents 
a major global health problem, also considering that its 
incidence increases progressively with aging of population 
[4]. 
The Child-Pugh score is used to assess the prognosis 
of chronic liver disease, mainly cirrhosis [5]. Patients are 
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classified according to different expected survivals from 
A to C (two year survival: A 85%, B 57%, C 35%) based 
on five clinical measures of liver disease (total bilirubin, 
serum albumin, prothrombin time, ascites, hepatic 
encephalopathy). The American and European Societies 
for the Study of the Liver endorse the Barcelona Clinic 
Liver Cancer (BCLC) classification system for staging and 
allocation to treatment in patients with HCC [6]. Using 
this classification, as others applied in the Asia-Pacific 
Countries, the therapeutic algorithm varies depending 
on the stage of disease, ranging from curative treatments 
(such as resection, ablation or transplantation) to palliation 
and best supportive care. Overall, only a minority of 
patients with HCC receive curative treatments and no 
more than 5% are eligible for liver transplantation [7]. 
In current practice, advanced stage patients present 
as such in 60-70% of cases while the rest progresses to 
this stage despite treatment of more precocious cancer 
presentations [6]. Prospective randomized controlled 
trials (RCTs) have shown that sorafenib prolongs survival 
in all subtypes of advanced HCC patients [8, 9] but side 
effects may lead to discontinuation of this treatment in up 
to 45% of patients. As a consequence, a significant number 
of advanced HCC patients may be precluded from the 
therapeutic benefit of sorafenib for related toxicities [10, 
11].
In the intermediate HCC stage, a wide range of 
interventional loco-regional treatments are available 
and trans-arterial chemoembolization (TACE) variously 
administered, is considered as the standard of care [4, 
6]. Also in advanced HCC - particularly when tumour 
extension is confined to the liver and when it is associated 
with a preserved hepatic function - the search for a 
tolerated loco-regional intervention able to challenge 
systemic therapy has been repeatedly investigated.
Trans-arterial radioembolization (TARE), often 
referred as a form of selective internal radiation 
therapy (SIRT) is a recognized, although not explicitly 
recommended therapy in several guidelines on clinical 
management of non-resectable HCC [4, 6, 12]. According 
to the latest release of the ESMO guidelines, however, 
TARE may compete with sorafenib in intermediate stage 
patients with prior TACE failure or advanced patients 
with tumoural macrovascular invasion (i.e. portal vein 
thrombosis, PVT) with no extra-hepatic spread and good 
liver function [12].
On technical grounds, TARE is a catheter-based 
interventional procedure that allows the emission of 
β-radiations at therapeutic levels directly into the tumour 
through its feeding arteries. Such a delivery mechanism, 
as for TACE, is aimed at minimizing the damage to the 
healthy liver parenchyma adjacent to the tumour. The main 
mechanism of action of TARE is a local brachytherapy 
and, unlike TACE, it doesn’t result in microvascular 
embolization and tumour ischemia [13]. Devices for 
radioembolization are commercially available in both 
form of implantable glass (Theraspere®) or biocompatible 
resin-based (SIR-Spheres®) radioactive (Yttrium90 - Y90) 
spheres [13].
In the light of the increasing use of this 
innovative therapy in clinical practice, this study aims 
to systematically review the available evidence for the 
clinical efficacy and safety of TARE (glass or resin-based) 
in patients with intermediate-advanced stages HCC. 
RESULTS
Out of 6641 references screened, 26 studies met 
the selection criteria. The study selection process is 
summarized in Figure 1.
The vast majority of included studies were 
observational cohorts, however three comparative studies 
were found: two RCTs comparing TARE with either 
TARE + sorafenib [14] or TACE [15] and a propensity-
score matching design study with sorafenib [16]. In 
Supplementary Table 1 a detailed description of all 26 
studies is given. 
A summary of the critical appraisal of TARE studies 
is reported in Supplementary Table 2. 
All studies showed low to medium methodological 
quality. One study [20] did not present clearly inclusion 
and exclusion criteria and only 3 studies [15, 27, 36] 
were conducted in more than one centre. No therapy was 
reported as concurrently administered but in 7 studies 
follow-on treatments were described. Nine studies had 
a prospective design while dropouts were adequately 
described in only 3 studies. 
Outcome measures
Studies presenting OS or TTP data, stratified by 
presence or absence of PVT were all included in the meta-
analyses except for two studies, one which did not report 
survival curves [17] and the second [37] which reported 
only survival data stratified by treatment dose, good or 
poor candidate groups and surgery vs. no surgery groups.
Studies considering patients with extrahepatic 
spread [26] or patients with deteriorated liver function 
(Child-Pugh C stage) [18] or patients awaiting.liver 
transplantation [14] were excluded from the analysis. 
Details on the 21 studies included in the quantitative 
analyses are listed in Table 1 together with patients and 
treatment characteristics.
The pooled OS was 63% (95% CI: 56-70%) and 
27% (95% CI: 21-33%) at 1- and 3-years respectively, 
for the population receiving TARE at an intermediate-
advanced stage (namely in unresectable HCC lacking 
demonstration of PVT: Figure 2A), whereas OS was 37% 
(95% CI: 26-50%) and 13% (95% CI: 9-18%) at the same 
follow-up times in patients with sufficient liver function 
but with an advanced HCC because of presence of PVT 
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Table 1: Characteristics of studies on radioembolization (TARE) included in the meta-analysis
Study Study type Patients characteristics Child-Pugh (A-B-C) % Patients with PVT
N arm 
TARE
Woodall 2009 
[19] Cohort
20 patients without PVT who 
received SIR, 15 patients with 
PVT who were treated. Of the PVT 
patients treated, 67% had portal VT, 
7% had cava PVT, and 26% had both
Patients without PVT: 
25% - 65% - 10% 
Patients with PVT: 20% - 53% 
- 27%
43% 35
Carr 2010 [20] Cohort
HCC (with or without PVT) 
considered unsuitable for resection, 
RFA, or liver transplantation
NA 28% 99
Hilgard 2010 [21] Cohort Advanced HCC and liver cirrhosis (with or without PVT) 78% - 22% - 0% 31% 108
Kooby 2010 [22] Cohort Unresectable HCC (with or without PVT) 48% - 52% - 0% 52% 27
Salem 2010 [23] Cohort HCC (with or without PVT) 45% - 52% - 3% 43% 291
Tsai 2010 [24] Cohort HCC with main (n=10) or first (n=12) branch PVT 55% - 27% - 5% (NA 13%) 100% 22
Lambert 2011 
[25] Cohort
Patients suffering from HCC  (with 
or without PVT) with the disease 
confined to the liver but not amenable 
to surgery, RFA or transplantation.
92% - 8% - 0% 7% 29
Sangro 2011 [27] Cohort (retrospective)
Patients with unresectable HCC (with 
or without PVT) 83% - 17% - 0% 23% 325
Mazzaferro 2013 
[28] Phase II
Consecutive cohort of 52 patients 
with liver cirrhosis and HCC (with 
or without PVT) confined to the 
liver and not eligible to conventional 
curative treatments
83% - 17% - 0% 67% 52
Moreno-Luna 
2013 [29]
Cohort 
(retrospective)
patients with unresectable HCC 
without PVT
87% - 13% - 0% 0% 61
Weng 2013 [30] Cohort HCC patients with PVT NA 100% 149
Gramenzi 2014 
[16]
Cohort 
(retrospective) HCC patients (with or without PVT)
91% - 9% - 0% 41% 32
Khor  2014 [31] Cohort Patients with HCC (with or without PVT) unsuitable for surgical resection 59% - 38% - 3% 31% 103
Kwok 2014 [32] Cohort Inoperable HCC (with or without PVT) 83% - 17% - 0% 63% 30
Padia 2014 [33] Cohort Unresectable HCC (with or without PVT) 55% - 40% - 5% 60% 20
Saxena 2014 [34] Cohort (retrospective)
HCC patients not amenable to 
curative surgical resection 67% - 22% - 2% (NA 9%) NA 45
She 2014 [35] Cohort Patients with unresectable advanced HCC (with or without PVT) 94% - 6% - 0% 50% 16
El Fouly 2015 
[36] Cohort
HCCs classified as intermediate stage 
(BCLC B) without PVT 84% - 16% - 0% 0% 44
Kolligs  2015 
[15] RCT
Patients with unresectable HCC, 
Child-Pugh ≤B7, ECOG performance 
status ≤2 and ≤5 liver lesions without 
extrahepatic spread, without PVT
92% - 8% - 0% 0% 13
Ozkan 2015 [38] Cohort HCC patients (with or without PVT) 90% - 10% - 0% 41% 29
Soydal 2015 [39] Cohort (retrospective)
Patients with unresectable HCC 
lesions NA NA 28
HCC = Hepatocellular carcinoma, PVT = portal vein thrombosis, TARE = trans-arterial embolization, BCLC = Barcelona 
Clinic Liver Cancer classification, ECOG = Eastern Cooperative Oncology Group, NA = not available
Oncotarget72346www.impactjournals.com/oncotarget
(Figure 2B).
When the entire population of patients receiving 
TARE was considered, with no stratification on PVT - 
i.e. with a case-mix of intermediate and advanced HCC 
- the OS was 58% (95% CI: 48-67%) and 17% (95% CI: 
12-23%) at 1- and 3-years respectively (Supplementary 
Figure 1). In the cumulative analysis the percentage of 
patients with PVT was 38% while those with suboptimal 
liver function (Child-Pugh non-A) were 21%. Both these 
well-known prognostic variables likely influenced the 
observed results, although a direct evidence of that could 
not be inferred from the available data. 
In terms of TTP, only four studies reported clear 
data: two of them had non-stratified TTP curves [21, 36], 
in one study data were stratified by Child-Pugh stage and 
BCLC classifications [23] and only one study stratified 
data on presence/absence of PVT [28]. Cumulative 
probability of progression in intermediate-advanced HCC 
lacking PVT at 1- and 2-years was 41% (95% CI: 29-54%) 
and 64% (95% CI: 52-76%) respectively (Figure 3A) 
while in advanced HCC carrying PVT TTP increased to 
69% (95% CI: 51-83%) at both 1 and 2 years in a single 
study (Figure 3B). When the entire population of patients 
receiving TARE - with intermediate 55% and advanced 
45% HCC - were pooled, the observed progression 
probability was 56% (95% CI: 41-70%) and 73% (95% 
CI: 56-87%) at 1 and 2 years respectively (Supplementary 
Figure 2). 
All results were confirmed in fixed effect meta-
analysis models (data not shown).
Liver impairment after TARE
As described above, tumour progression after TARE 
was reported as a late event mainly due to deterioration of 
performance status and of Child-Pugh stage.
More specifically, the analysis on the adverse events 
related to TARE was focused on liver decompensation 
and/or failure following treatment. There was a large 
heterogeneity in definition of liver decompensation in 
the included studies and with that bias the percentage 
of patients suffering liver decompensation after TARE 
is reported in Table 2. In particular, TARE-related liver 
impairment events ranged from 0-1% in some studies to 
36.5% in others depending on the number of treatments 
received, performance status, duration and type of pre-
TARE treatments. Liver decompensation was more 
likely in patients with multiple pre-TARE therapies 
and borderline cirrhosis (HR: 3.2; 95% CI: 1.8-9.7) as 
previously reported [40]. Medium time from TARE to 
liver decompensation was 3 months (range: 1-6).
DISCUSSION
In the last decade trans-arterial radioembolization 
has emerged as a viable loco-regional treatment option 
for patients with unresectable hepatocellular carcinoma 
associated or not with portal vein thrombosis, although 
its use is still not formally recommended in clinical 
guidelines due to lack of prospective randomized studies. 
While large RCTs have been implemented and likely to 
Figure 1: Study flow chart
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Table 2: Liver failure after TARE and study characteristics
Study
% of patients 
with liver 
impairment
Time from 
TARE 
(months)
Mean number of 
treatments per 
patient
Intervention Mean dose Previous treatments
Woodall 
2009 [19] 10% NC
PVT patients: 2; no 
PVT patients: 1.5 TARE (Therasphere)
median dose of 120 
Gy (range 120-142) NA
Carr 2010 
[20] NA NA
Single, planned 
treatment, but 30% 
required a second 
treatment because of 
new, late appearing 
lesions
TARE (Therasphere) from 135 to 150 Gy to the treated lobe NA
Hilgard 2010 
[21] 2.78% 1 1.47 TARE (Therasphere) 120±8 Gy
62% of patients were 
therapy-naive; the rest 
received prior local 
therapy with curative 
or palliative intent
Kooby 2010 
[22] 22% 1 1.2±1.1 TARE (SIR-Spheres)
740-2220 MBq per 
lobe NA
Salem 2010 
[23] 19% NC 1.8 TARE (Therasphere)
The median dose 
was 103 Gy per 
treatment (95% CI 
99–108)
Resection 5%, RFA 
2%, TACE 5%, 
Orthotopic liver 
transplantation 1%
Tsai 2010 
[24] 13%* 1 1.45
Resin or glass 
microspheres
2.7 GBq (range 
0.59-9.21) NA
Lambert 
2011 [25] 3%
in the 
weeks 
following 
treatment
1.2 TARE (Therasphere) 2.17 GBq, range 0.73 to 3.99 GBq
RFA 13.7%, Liver 
resection and 
radiolabelled Lipiodol 
3.4%, Transplantation 
and subsequent 
sorafenib 3.4%
Sangro 2011 
[27] 5.80% 3 1.08 TARE (Therasphere)
1.6 GBq (range 
0.3-4.0)
TARE or TACE 
(27.4%), surgical 
resection or 
transplantation 
(18.2%), 
percutaneous ablation 
(9.2%)
Mazzaferro 
2013 [28] 36.50% 6 1.12 TARE (Therasphere)
median 2.6 GBq 
(range 1.1-5.7); 
median dose to liver 
lobe 101 Gy per 
treatment (range 
34-146)
RFA 13.5%, Liver 
resection 15.4%
Moreno-
Luna 2013 
[29]
0% 1.28 TARE (Therasphere) The target dose of 80–150 Gy NA
Weng 2013 
[30] NA NA TARE (Therasphere) NA NA
Gramenzi 
2014 [16]
9% (grade 
3-4) in the 
whole group 
of patients
6
Median tumour dose 
263.2 Gy (range 16.6–
1145.8); Total injected 
activity 1.83 GBq 
(0.45–2.41)
TARE (SIR-Spheres)
median tumor 
dose was 119.8 Gy 
(range, 31.4–420.2 
Gy)
Resection 13.6 %, 
RFA 12.6%
Khor  2014 
[31] 1% NC 1.175 TARE (SIR-Spheres)
All patients 
received more than 
2 GBq of Y90
NA
Kwok 2014 
[32] 13% 3 NA TARE (SIR-Spheres)
Median dose to 
treated segment 
254Gy, median 
dose to the tumor 
536 Gy
Ablation 20%, 
chemoembolization 
5%, radioembolization 
5%
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be reported in the near future, the present study aimed at 
identifying the available evidence around the efficacy and 
safety of TARE through a systematic review of published 
studies conducted on patients with intermediate and 
advanced HCC.
We identified 23 observational cohort studies, two 
RCTs of TARE vs. TARE + sorafenib and TARE vs. TACE 
and one propensity score matching study comparing 
TARE vs. sorafenib. All studies were of intermediate 
to low methodological quality. After excluding papers 
not presenting the outcomes of interest (OS or TTP) in 
a suitable form for the meta-analysis, a pooled summary 
estimate on the 21 remaining studies confirmed the good 
efficacy performance of TARE in HCC unsuitable for 
curative treatment options.
Included studies suggest that median OS in patients 
receiving TARE for intermediate-advanced HCC falls 
in the range of 12-24 months, halved to 6-12 months 
should PVT be present. Pooled survival rates at 3-years 
after TARE were estimated as 13% (with PVT) and 27% 
(without PVT). These results are consistent with those 
presented in other published studies reporting median OS 
of 7-41.6 months in BCLC B to C patients [41]. 
Residual heterogeneity among studies - as measured 
by I2 - was observed particularly in TTP while being 
less evident for OS. This reflected different schedules 
and protocols for definition and identification of tumour 
progression, which is considered a secondary endpoint 
in the large majority of studies [42]. High heterogeneity 
was detected also when definition of liver decompensation 
related to TARE was taken into account; this forced us 
to compute and summarize data on adverse events only 
in a qualitative fashion. Despite such limitation, TARE-
related liver toxicity was registered in less than 30% of 
patients with near to zero mortality directly related to the 
procedure and an average hospital stay claimed as shorter 
or equal compared to conventional chemoembolization 
[13].
This review has a number of limitations. First, only 
English language studies were included: considering 
that several clinical studies retrieved were conducted 
in non-English speaking countries, it is possible that 
some evidence on the clinical role of TARE has been 
overlooked. Moreover, individual level data used in the 
selected studies were not accessible. Individual rather than 
aggregate data, would have enriched the overall analysis 
[43]. 
As regards to the clinical outcomes, the number of 
papers in which post-progression survival after TARE is 
described is very limited, although sorafenib is used quite 
often as second-line therapy after TARE, thus affecting 
post-progression and overall survival. This was an 
unavoidable bias assumed to be equally distributed among 
the studies and therefore not considered as an exclusion 
driver. Inclusion of post-progression therapies reflected in 
fact the field practice adopted in the management of HCC 
patients.
The evidence that supports the use of 
radioembolization in HCC is based on retrospective 
or prospective cohort studies and no RCTs have been 
published comparing TARE with systemic therapies, in 
particular sorafenib, currently the mainstay for treating 
advanced HCC. 
Large-scale randomized controlled trials with 
Padia 2014 
[33] 10% NC 1 TARE (Therasphere)
1.49 GBq (range 
0.34-2.50)
Liver resection 
13%, transarterial 
chemoembolization 
or hepatic artery 
chemoinfusion 24%, 
ablative therapy 
9%, at least one 
line of systemic 
chemotherapy 13%
Saxena 2014 
[34] 4.40% NC NA
TARE (SIR-
Spheres) NA NA
She 2014 
[35] 6.30% NC NA
TARE (not 
specified) NA
Resection 7%, RFA 
11%, TACE 32%
El Fouly 
2015 [36] 9.09% 1 1.4 ±0.6 TARE (Therasphere)
median 1.6±0.6 
GBq NA
Kolligs  
2015 [15] <5% 4 1
TARE (SIR-
Spheres)
1.5 GBq (range 
1-2.2) 34.50%
Ozkan 2015 
[38] 0% NA
resin or glass 
microspheres 1.5 ± 0.2 GBq
None of them had 
received prior 
treatment before SIRT
Soydal 2015 
[39] NA NA
Treatment was applied 
to the right lobe in 22 
patients and both lobes 
in 6 patients
TARE (resin) NA NA
* % on the number of treatments performed
TARE = trans-arterial radioembolization, TACE = trans-arterial chemoembolization, RFA = radio-frequency ablation, SIRT 
= selective internal radiation therapy, NC = not clear, NA  = not available
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Figure 2: A. Overall survival rates at different follow-up times in intermediate-advanced HCC patients without PVT receiving TARE B. 
Overall survival rates at different follow-up times in advanced HCC patients with PVT receiving TARE
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overall survival as a primary endpoint exploring this 
comparison have been started (SIRveNIB NCT01135056, 
SARAH NCT01482442, YES-P NCT01887717). These 
trials and future prospective randomized studies of 
TARE vs. suitable comparators, are crucial to provide 
direct evidence to evaluate comparative effectiveness 
because, at least in advanced HCC radioembolization 
may achieve overall survivals in the range of 6-10 months 
[27] competitive with the survival range (6.5-10.7 months) 
reported in the phase III clinical trials registering sorafenib 
as a standard of care.
Unfortunately, a pooled analysis focused on tumor 
Figure 3: A. Probability of tumor progression at different follow-up times in intermediate-advanced HCC patients without PVT receiving 
TARE. B. Probability of tumor progression at different follow-up times in advanced HCC patients with PVT receiving TARE.
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response was not feasible due to high heterogeneity in 
reporting this outcome across the included studies. In 
fact, different response criteria (i.e. Response Evaluation 
Criteria In Solid Tumors - RECIST, mRECIST, World 
Health Organization - WHO criteria), imaging techniques, 
and time of radiological evaluation prevented a reliable 
assessment of this secondary endpoint. However, tumor 
response usually represents only a surrogate endpoint 
whereas OS, which is universally considered the primary 
outcome in oncological studies, was consistently assessed 
in our meta-analysis.
Among the studies comparing TACE versus TARE, 
two used Drug Eluting Beads TACE (DEB-TACE) [26, 
29] and five conventional TACE (cTACE) [15, 20, 22, 35, 
36]. Although subgroup analysis according to the adopted 
TACE regimen was unfeasible due to the low number 
of studies, we know from previous cohort studies that 
DEB-TACE and cTACE lead to similar outcomes and 
comparable side effects in HCC patients [44, 45].
Observational data allow a preliminary assessment 
of the incremental costs vs. incremental effectiveness (i.e. 
cost-effectiveness) of TARE vs. sorafenib and help in this 
setting to assess the value of presumably similar treatment 
options in field practice. In a recent cost-effectiveness 
analysis of TARE vs. TACE, patients with advanced 
BCLC-C were found to benefit from radioembolization 
at an increased cost [46] while in patients with BCLC-A 
disease, who formally lack survival benefit from 
radioembolization, cost-efficacy could be obtained in some 
specific subgroups, such as PVT or technical unfeasibility 
of curative approaches. In the future, a cost-effectiveness 
analysis could be performed comparing TARE with the 
other available therapies, particularly sorafenib, to identify 
whether this procedure is cost-effective or not, and to 
profile HCC subgroups which could benefit from TARE 
at a reasonable cost. This analysis could be instrumental 
in helping policy-decision making, while additional post-
marketing evidence is collected.
Given the findings of this systematic review, 
based on safety and efficacy data from included studies, 
until the results of the ongoing trials become available, 
radioembolization appears to be a viable treatment option 
for patients with intermediate-advanced stage HCC.
MATERIALS AND METHODS
Literature search
This review adopts the Preferred Reporting Items 
for Systematic Reviews and Meta-Analysis (PRISMA) 
statement [47]. In May 2015, a systematic search was 
conducted on PubMed, Embase, the Cochrane Library and 
Web of Science databases to retrieve clinical evidence on 
TARE for HCC. The search strategy was developed using 
the PICOS (Patient, Intervention, Comparator, Outcome, 
Study) framework. Boolean operators “AND” and “OR” 
were used to combine terms, while “NOT” operator was 
not included following Cochrane indications. Studies 
were considered if published in English and related to an 
adult population (≥18 years old). Reference lists of the 
retrieved articles were screened to find additional studies 
not identified through the original search. 
Selection criteria
Inclusion criteria are shown in Table 3. Given 
common indications emerging for Y90, the review was 
conducted with a focus on patients with intermediate and 
advanced HCC stages according to BCLC staging system 
(stages B and C), the latter particularly when presenting 
with PVT.
Data extraction
Abstracts and full-text selection was conducted 
independently by two expert reviewers (CR, SS). In case 
of debate on study eligibility a third senior reviewer (AF) 
Table 3: PICOS inclusion criteria
Population
Studies considering adult population (≥18 years) with intermediate and advanced 
HCC* according with the BCLC staging system
*studies reporting data stratified for PVT presence were categorized separately
Intervention TARE using Y90-embedded glass or resin microspheres
Comparator Not specified
Outcome measures Overall survival; recurrence/progression-free survival, time to progression, safety
Study types
Validation studies; controlled clinical trials; randomized controlled trials; 
observational studies (case-report, letters, comments, editorials and non-
systematic review were excluded)
Availability English; full text
Time and place Date and place limits were not set
HCC = Hepatocellular carcinoma, BCLC = Barcelona Clinic Liver Cancer classification, TARE = trans-arterial 
radioembolization, PVT = portal vein thrombosis
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was involved to reach consensus. Data were extracted 
using a customized template developed in Microsoft Excel 
based on the PICOS statement. Information recorded 
included study features, participants’, intervention’s and 
comparator’s characteristics, safety and efficacy outcomes. 
Data analysis
Data referring to TARE were retrieved from all 
comparative and non-comparative studies identified. 
Relevant efficacy outcomes (i.e. overall survival - OS - 
and time to progression - TTP - rates) were summarized 
and graphically presented through forest plots. When 
necessary, survival rates were derived from digitalization 
of Kaplan-Meier survival curves using the software Plot 
Digitizer 2.6.6©. OS was calculated as the difference 
between the date of the first treatment and the date of 
death from any cause, or last observation date in case 
of censoring. TTP was calculated from the first TARE 
treatment to the first progression at any site. Main adverse 
events, such as liver impairment, were tabulated and 
discussed qualitatively.
Survival rates for OS and TTP from different studies 
were pooled through a random effect meta-analysis of 
proportions with exact binomial confidence intervals [48]. 
A test on the summary effect measure is given, as well 
as a test for heterogeneity, also quantified using the I2 
metric [49]: the higher the values (from 0% to 100%) the 
larger the heterogeneity across studies. Fixed effect meta-
analyses were also performed to check the robustness of 
obtained estimates to alternative models specification. 
Results are displayed in forest plots according to follow-
up time and relevant patient subgroups. Analyses were 
performed using Stata® software (StataCorp, version 14). 
Quality assessment
The methodological quality of included studies was 
assessed according to a modified version of the National 
Health Service Centre of Review and Dissemination 
criteria [50]. Following this guidance, no scoring system 
was adopted; quality assessments were used for descriptive 
purposes [51].
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